AHRQ

AHRQ: New guideline illuminates path for managing genitourinary syndrome of menopause

July 25, 2025

At the heart of the new AUA/SUFU/AUGS guideline on genitourinary syndrome of menopause (GSM), which was informed by an AHRQ systematic review, is an emphasis on shared decision making between clinicians and patients. It advocates for screening at-risk individuals through focused history taking and recommends local low-dose vaginal estrogen as a primary treatment option. The guideline also endorses alternative treatments such as vaginal DHEA, ospemifene, vaginal moisturizers, and lubricants, while cautioning against the use of energy-based therapies. Importantly, the guideline addresses safety concerns, clarifying that local low-dose vaginal estrogen isn’t associated with increased endometrial cancer risk. It also offers valuable advice on managing GSM in breast cancer survivors, highlighting the need for multidisciplinary approaches.

Sources:

(2025, July 8). AHRQ News Now. New guideline illuminates path for managing genitourinary syndrome of menopause [Issue #965]. https://www.ahrq.gov/news/newsletters/e-newsletter/965.html#link_1

Kaufman MR, et al. (2025, April 29). J Urol. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. https://pubmed.ncbi.nlm.nih.gov/40298120/